Benefits and risks of using antidepressants in children and adolescents

Expert Opinion on Drug Safety

Volumn 7, Issue 1, 2008, Pages 9-27

  Bailly, Daniel ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

Adolescents; Antidepressants; Anxiety disorders; Children; Depressive disorders; Suicidality

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGGRESSION; AGITATION; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; BEHAVIOR DISORDER; CHILD PSYCHIATRY; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; CONFUSION; DISEASE DURATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; EXCITABILITY; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEART DISEASE; HOSTILITY; HUMAN; HUMAN RELATION; MAJOR DEPRESSION; MENTAL DISEASE; MOOD DISORDER; MOTOR ACTIVITY; NOCTURNAL ENURESIS; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; ORTHOSTATIC HYPOTENSION; PSYCHOSIS; RESTLESSNESS; REVIEW; RISK BENEFIT ANALYSIS; SEPARATION ANXIETY; SIDE EFFECT; SLEEP DISORDER; SOCIAL ISOLATION; SOCIAL PHOBIA; SUDDEN DEATH; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TREMOR; URTICARIA; VERTIGO; XEROSTOMIA;

ADOLESCENT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CHILD; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; MENTAL DISORDERS; RISK FACTORS; SELF-INJURIOUS BEHAVIOR;

EID: 38949214329     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.1.9     Document Type: Review

References (127)

1. Zito JM, Safer DJ, Dosreis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003;157(1):17-25
2. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB. Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 1999;38(5):557-65
3. Murray ML, Thompson M, Santosh PJ, Wong IC. Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf 2005;28(12):1151-7
4. Volkers AC, Heerdink ER, Van Dijk L Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf 2007;16(9):1054-62
5. Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007;64(4):466-72
6. Institut National De La Sante Et De La Recherche Medicale. Données épidémiologiques. In: Troubles mentaux. Dépistage et prévention chez l'enfant et l'adolescent. Les éditions Inserm, Paris 2002. pp. 3-67
7. Emslie GJ, Rush J, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54(11):1031-7
8. Emslie GJ, Mayes TL. Mood disorders in children and adolescents: psychopharmacological treatment. Biol Psychiatry 2001;49(12):1082-90
9. Courtney DB. Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials. Can J Psychiatry 2004;49(8):557-63
10. Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL. Efficacy and safety of antidepresants for children and adolescents. BMJ 2004;328(7444):879-83
11. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363(9418):1341-5
12. Bridge JA, Salary CB, Birmaher B, Asare AG, Brent DA. The risks and benefits of antidepressant treatment for youth depression. Ann Med 2005;37(6):404-12
13. Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 2005;46(7):735-54
14. Hjalmarsson L, Corcos M, Jeammet P. Indication des inhibiteurs de la recapture de la sérotonine au cours d'un épisode dépressif majeur chez l'enfant et l'adolescent (bénéfices/risques). L'Encéphale 2005;31(3):309-16
15. Andrade C, Bhakta SG, Singh NM. Controversy revisited: selective serotonin reuptake inhibitors in paediatric depression. World J Biol Psychiatry 2006;7(4):251-60
16. Bailly D. Eflicacité des antidépresseurs inhibiteurs sélectifs de la recapture de la sérotonine chez l'enfant et l'adolescent. Presse Med 2006;35(9):1293-302
17. Wallace AE, Neily J, Weeks WB, Friedman MJ. A cumulative meta-analysis of selective serotonin reuptake inhibitors in pediatric depression: did unpublished studies influence the efficacy/safety debate? J Child Adolesc Psychopharmacol 2006;16(1-2):37-58
18. Papanikolaou K, Richardson C, Pehlivanidis A, Papadopoulou-Daifoti Z. Efficacy of antidepressants in child and adolescent depression: a meta-analytic study. J Neural Transm 2006;113(3):399-415
19. Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2007;46(4):479-88
20. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297(15):1683-96
21. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003;290(8):1033-41
22. Mayes TL, Tao R, Rintelmann JW, et al. Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine? CNS Spectr 2007;12(2):147-54
23. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Carmody T, Mayes TL. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depress Anxiety 1998;7(1):32-9
24. Brent DA, Holder D, Kolko D, et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry 1997;54(9):877-85
25. Mufson L, Weissman MM, Moreau D, Garfinkel R. Efficacy of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 1999;56(6):573-9
26. Mufson L, Dorta KP, Wickramaratne P, Nomura Y, Olfson M, Weissman MM. A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 2004;61(6):577-84
27. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004;292(7):807-20
28. Kennard B, Silva S, Vitiello B, et al. Remission and residual symptoms after short-term treatment in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45(12):1404-11
29. Kratochvil C, Emslie G, Silva S, et al. Acute time to response in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45(12):1412-18
30. Vitiello B, Rohde P, Silva S, et al. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45(12):1419-26
31. Curry J, Rohde P, Simons A, et al. Predictors and moderators of acute outcome in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45(12):1427-39
32. Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38(5):513-16
33. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995;310(6984):897-901
34. Hazell P, O'Connell D, Heathcore D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002;2:C0002317
35. Conners CK. Methodology of antidepressant drug trials for treating depression in adolescents. J Child Adolesc Psychopharmacol 1992;2(1):11-22
36. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40(7):762-72
37. Braconnier A, Le Coent R, Cohen D. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 2003;42(1):22-9
38. Geller DA, Biederman J, Stewart SE, et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003;160(11):1919-28
39. March JS, Klee BJ, Kremer CM. Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents. J Child Adolesc Psychopharmacol 2006;16(1-2):91-102
40. Cook EH, Wagner KD, March JS, et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2001;40(10):1175-81
41. Wagner KD, Cook EH, Chung H, Messig M. Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2003;13(Suppl 1):S53-S60
42. Geller DA, Biederman J, Stewart SE, et al. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? J Child Adolesc Psychopharmacol 2003;13(Suppl 1):S19-S29
43. Yaryura-Tobias JA, Grimes MS, Walz J, Neziroglu F. Parental obsessive-compulsive disorder as a prognostic factor in a year long fluvoxamine treatment in childhood and adolescent obsessive-compulsive disorder. Int Clin Psychopharmacol 2000;15(3):163-8
44. Piacentini J. Cognitive behavioral therapy of childhood OCD. Child Adolesc Psychiatr Clin North Am 1999;8(3):599-616
45. Nesiroglu F, Yaryura-Tobias JA, Walz J, McKay D. The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2000;10(4):295-306
46. Pediatric OCD Treatment Study (POTS) team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004;292(16):1969-76
47. Grados M, Scahill L, Riddle MA. Pharmacotherapy in children and adolescents with obsessive-compulsive disorder. Child Adolesc Psychiatr Clin North Am 1999;8(3):617-34
48. Leonard HL, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48(10):922-7
49. Rettew DC, Swedo SE, Leonard HL, Lenane MC, Rapoport JL. Obsessions and compulsions across time in 79 children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992,31(6):1050-6
50. Swedo SE, Rapoport JL. Phenomenology and differential diagnosis of obsessive compulsive disorder in children and adolescents. In: Obsessive Compulsive Disorder in Children and Adolescents. Rapoport JL, editor. American Psychiatric Press, Washington DC; 1989. pp. 13-32
51. Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003;42(4):415-23
52. Walkup J, Labellarte M, Riddle MA, et al. Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study. J Child Adolesc Psychopharmacol 2002;12(3):175-88
53. James A, Soler A, Weatherall R. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2005;4:CD004690
54. In-Albon T, Schneider S. Psychotherapy of childhood anxiety disorders: a meta-analysis. Psychother Psychosom 2007;76(1):15-24
55. Barrickman LL, Noyes R, Kuperman S, Schumacher E, Verde M. Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry 1991;30(5):762-7
56. Quintana H, Butterbaugh GJ, Purnell W, Layman AK. Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents. Child Psychiatry Hum Dev 2007;37(3):241-53
57. Olvera RL, Pliszka SR, Luh J, Tatum R. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 1996;6(4):241-50
58. Mukaddes NM, Abali O. Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. Psychiatry Clin Neurosci 2004;58(1):92-5
59. Findling RL, Greenhill LL McNamara NK, et al. Venlafaxine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17(4):433-46
60. Emslie GJ, Walkup JT, Pliszka SR, Ernst M. Nontricyclic antidepressants: current trends in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38(5):517-28
61. Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 2002;63(Suppl 12):16-22
62. Bailly D, Vaiva G. Treatment of attention deficit/hyperactivity disorder with monoamine oxidase inhibitors from childhood to adulthood. In: Attention Deficit Hyperactivity Disorder (ADHD) Research. Larimer MP, editor. Nova Science Publishers, Inc., New York 2005. pp. 189-205
63. Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(5):841-5
64. Mohammadi MR, Ghanizadeh A, Alaghband-Rad J, Tehradidoost M, MesgarpouR B, Soon H. Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized Clinical trial. J Child Adolesc Psychopharmacol 2004; 14(3):418-25
65. Rubunstein S, Malone MA, Roberts W, Logan WJ. Placebo-controlled study examining effects of selegiline in children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2006;16(4):404-15
66. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34(5):649-57
67. Donnelly M, Zametkin AJ, Rapoport JL, et al. Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamune levels, and clinical response. Clin Pharmacol Ther 1986;39(1):72-81
68. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD. I. Efficacy. J Am Acad Child Adolesc Psychiatry 1989;28(5):777-84
69. Rapoport JL, Quinn PO, Bradbard G, Riddle KD, Brooks E. Imipramine and methylphenidate treatments of hyperactive boys. A double-blind comparison. Arch Gen Psychiatry 1974;30(6):789-93
70. Werry J, Aman MG, Diamond E. Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry 1979;21(1):27-35
71. Gualtieri CT, Evans RW. Motor performance in hyperactive children treated with imipramine. Percept Mot Skills 1988;66(3):763-9
72. Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995;95(1):74-81
73. Spencer T, Biederman J, Coffey B, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2002;59(7):649-56
74. Quinn PO, Rapopart JL. One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. Am J Psychiatry 1975;132(3):241-45
75. Riddle MA, King RA, Hardun MT, et al. Behavioral side effects of fluoxetine in children and adolescents. J Child Adolesc Psychopharmacol 1991;1(2):193-8
76. King RA, Riddle MA, Chappell PB, et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 1991;30(2):179-86
77. Cole JO, Bodkun JA. Antidepressant drug side effects. J Clin Psychiatry 1990;51(Suppl):21-6
78. Tierney E, Joshi PT, Llinas JF, Rosenberg LA, Riddle MA. Sertraline for major depression in children and adolescents: preliminary clinical experience. J Child Adolesc Psychopharmacol 1995;5(1):13-27
79. Walkup JT. A differential diagnosis of the adverse behavioral effects of fluoxetine. Newsl Am Acad Child Adolesc Psychiatry 1994;25(3):28-30
80. March JS, Biederman J, Wolkaw R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998;280(20):1752-6
81. Emslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry 2006;45(12):1440-55
82. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med 2001;344(17):1279-85
83. Bailly D. Tolérance des antidépresseurs inhibiteurs sélectifs de la recapture de la sérotonine chez l'enfant et l'adolescent. Presse Med 2006;35(10):1507-15
84. Gualtieri CT, Johnson LG. Antidepressant side effects in children and adolescents. J Child Adolesc Psychopharmacol 2006;16(1-2):147-57
85. Zuckerman ML, Vaughan BL, Whitney J, et al. Tolerability of selective serotonin reuptake inhibitors in thirty-nine children under age seven: a retrospective chart review. J Child Adolesc Psychopharmacol 2007;17(2):165-74
86. Wilens TE, Biederman J, Kwon A, et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 2003;13(2):143-52
87. Wong IC, Besag FM, Santosh PJ, Murray ML. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf 2004;27(13):991-1000
88. Mosholder AD, Willy M. Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis. J Child Adolesc Psychopharmacol 2006; 16(1-2):25-32
89. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63(3):332-9
90. Wohlfarth TD, Van Zwieten BJ, Lekkerkerker FJ, et al. Antidepressants use in children and adolescents and the risk of suicide. Eur Neuropsychopharmacol 2006;16(2):79-83
91. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147(2):207-10
92. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005;330(7488):396
93. Aursnes I, Tvete IF, Gaasemyr J, Natvig B. Even more suicide attempts in clinical trials with paroxetine randomised against placebo. BMC Psychiatry 2006;6:55
94. Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004;61(11):1153-62
95. Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004;43(11):1387-96
96. Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003;60(10):978-82
97. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006;163(11):1898-904
98. Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ. Antidepressants and suicide risk in the United States, 1985-1999 J Clin Psychiatry 2004;65(11):1456-62
99. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005;62(2):165-72
100. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292(3):338-43
101. Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005;330(7488):389
102. Didham RC, McConnell DW, Blair HJ, Reith DM. Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication. Br J Clin Pharmacol 2005;60(5):519-25
103. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006;63(12):1358-67
104. Valuck RJ, Libby AM, Sills MR, Giese AA, Allen RR. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004;18(15):1119-32
105. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry 2006;63(8):865-72
106. Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 1992;268(24):3441-5
107. Gibbons RD, Brown CH, Hut K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007;164(9):1356-63
108. Nilsson M, Joliat MJ, Miner CM, Brown EB, Heiligenstein JH. Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. J Child Adolesc Psychopharmacol 2004;14(3):412-17
109. Warden SJ, Roblung AG, Sanders MS, Bliziotes MM, Turner CH. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005;146(2):685-93
110. Pine DS. Treating children and adolescents with selective serotonin reuptake inhibitors: how long is appropriate? J Child Adolesc Psychopharmacol 2002;12(3):189-203
111. Landry M, Frasier M, Chen Z, et al. Fluoxetine treatment of prepubescent rats produces a selective functional reduction in the 5-HT2A receptor-mediated stimulation of oxytocin. Synapse 2005;58(2):102-9
112. Ryan ND. Heterocyclic antidepressants in children and adolescents. J Child Adolesc Psychopharmacol 1990;1(1):21-30
113. Preskorn SH, Weller E, Jerkovich G, Hughes CW, Weller R. Depression in children: concentration-dependent CNS toxicity of tricyclic antidepressants. Psychopharmacol Bull 1988;24(1):140-2
114. Leeder JS. Ontogeny of drug-metabolising enzymes and its influence on the pathogenesis of adverse drug reactions in children. Curr Ther Res 2001;62(12):900-12
115. Findling RL, McNamara NK, Stansbrey RJ, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol 2006;16(1-2): 131-45
116. Leeder JS. Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov Today 2004;9(13):567-73
117. Berk M, Dodd S. Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression? Med Hypotheses 2005;65(1):39-43
118. Apter A, Lipschitz A, Fang R, et al. Evaluation of suicidal thoughts and behaviors in children and adolescents taking paraxetine. J Child Adolesc Psychopharmacol 2006;16(1-2):77-90
119. Bridge JA, Barbe RP, Birmaher B, Kolko DJ, Brent DA. Emergent suicidality in a clinical psychotherapy trial for adolescent depression. Am J Psychiatry 2005;162(11):2173-5
120. Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999;156(2):181-9
121. Mann JJ, Brent DA, Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology 2001;24(5):467-77
122. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78(5):804-14
123. Weisz JR, Jensen-Doss A, Hawley KM. Evidence-based youth psychotherapies versus usual clinical care: a meta-analysis of direct comparisons. Am Psychol 2006;61(7):671-89
124. Harrington R, Whittaker J, Shoebridge P, Campbell F. Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depressive disorder. BMJ 1998;316(7144):1559-63
125. Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy far depression in children and adolescents: a meta-analysis. Psychol Bull 2006;132(1):132-49
126. Nardi DA, Barrett S. Potential effects of antidepressant agents on the growth and development of children and adolescents. J Psychosoc Nurs Ment Health Serv 2005;43(1):22-35
127. Bailly D, Olivier N, Faessel AI. Stress de la période périnatale et troubles émotionnels - aspects biologiques. In: Psychiatric de l'enfant et de l'adolescent. Bailly D, editor. Doin Editeurs, Paris; 2002. pp. 179-94